The KAT2B Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the KAT2B gene has been disrupted to abolish functional protein expression. This loss-of-function model is generated through CRISPR/Cas9-mediated gene disruption, yielding a heterogeneous pool of edited cells suitable for studying the collective consequences of KAT2B inactivation. Unlike clonal lines, this polyclonal format captures the diversity of editing outcomes, providing a physiologically relevant system for investigating KAT2B??s roles in lung adenocarcinoma biology.
The A-549 cell line originates from human lung adenocarcinoma and displays epithelial morphology with characteristics of alveolar type II pneumocytes. These cells are widely employed in cancer research to model lung tumourigenesis, drug responses, and molecular mechanisms of oncogenesis. A-549 cells retain key features of the lung epithelial environment, making them a suitable platform for interrogating pathways that govern cell proliferation, apoptosis, and metastasis. Their well-characterized genetics and robust growth in culture facilitate reproducible CRISPR-based perturbation studies.
KAT2B (also known as PCAF) functions as a histone acetyltransferase and transcriptional coactivator, catalyzing acetylation of histones (notably H3K9 and H3K14) and non-histone proteins including p53 and c-Myc. This enzyme is activated by upstream regulators such as p53, E2F1, and c-Myc, and is also modulated by Akt and MAPK signaling. KAT2B acetylates p53, enhancing transcriptional activity toward targets like CDKN1A (p21) and BAX. It interacts with cofactors p300, CBP, TIP60, and TFIID, and forms complexes with NF-??B subunits, integrating signals from p53, NF-??B, TGF-??, and Wnt pathways. Thus, KAT2B coordinates transcriptional responses to stress, DNA damage, and proliferation.
In A-549 cells, KAT2B knockout reduces histone acetylation and impairs p53-mediated transcription of cell cycle arrest and pro-apoptotic genes, potentially enhancing proliferation and survival. As A-549 cells express wild-type p53, this model enables dissection of KAT2B-dependent acetylation without confounding p53 mutations. The polyclonal knockout cells are thus a tool to examine epigenetic dysregulation in tumor aggressiveness, chemoresistance, and apoptosis evasion in lung adenocarcinoma.
Research applications include investigating KAT2B roles in proliferation, apoptosis, and drug sensitivity. Assays such as western blotting for KAT2B and acetylated targets, RT-qPCR, RNA-seq, ChIP-qPCR, and functional assays (viability, Annexin V/PI, migration, invasion, drug sensitivity) are compatible. This model is suitable for screening compounds targeting epigenetic regulators or reactivating p53. For further technical inquiries, please contact Ascent Research.
